Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
New Horizon Health
Nominal: 62.800 RT Quote
Open-offer-subscription Rate: 4133x One Lot Success Rate: 2%

New Horizon Health Limited Founded in November 2015, it is the pioneer in China’s colorectal cancer screening market. Its mission is to advance the innovation and accelerate the adoption of cancer screening technologies in China.

ColoClear, its proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan. ColoClear targets high-risk colorectal cancer population in China, and enables users to collect stool sample at home and avoid invasive procedures while delivering high testing sensitivity and specificity.

The Group two home-based colorectal cancer screening tests, ColoClear and Pupu Tube, synergistically address target populations with various risk levels. Pupu Tube, its proprietary, non-invasive, stool-based FIT test, is the first and only self-conducted FIT screening product approved by NMPA in China. Pupu Tube targets mass market in China recommended for colorectal cancer screening to increase colorectal cancer screening awareness and identify high-risk population.

In addition, the Group has two late-stage product candidates for gastric and cervical cancer screening respectively. Its UU Tube, a stool-based self-conducted screening test for gastric cancer. It submitted registration application to NMPA in November 2020. It is also developing its CerviClear, a non-invasive urine-based home-use screening test for cervical cancer. It expects to initiate the registrational trial for CerviClear by as early as the last quarter of 2021.

The Group has built a portfolio of 71 patents and patent applications globally, including 17 countries or regions outside the PRC. It provides products to end-users through direct sales channels including hospitals, health checkup centers, insurance companies, pharmacies and online channels, and to a much lesser extent, through distributors.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot500
Registrar & Transfer OfficeTricor Investor Services
No. of Offer Shares76.60m shares
No. of International Offer Shares68.94m shares
No. of HK Offer Shares7.67m shares
Offer Price$22.70 - $26.66
Nominal ValueUS$ 0.00005 each
Stock Code6606
SponsorGoldman Sachs (Asia) L.L.C., UBS Securities Hong Kong Limited
UnderwritersGoldman Sachs (Asia) L.L.C., UBS AG Hong Kong Branch, Haitong International Securities Company Limited, BOCI Asia Limited, China Industrial Securities International Capital Limited, Daiwa Capital Markets Hong Kong Limited, VMS Securities Limited, Futu Securities International (Hong Kong) Limited
Application PeriodFeb 5 (Fri) - Noon, Feb 10 (Wed)
Price Determination DateOn or Before 5pm, Feb 10 (Wed)
Result Announcement DateOn or Before Feb 17 (Wed)
Dispatch of Shares and Refund ChequesOn or Before Feb 17 (Wed)
Dealings in Shares commence onFeb 18, 2021. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveYiyou CHEN (Chairman), Yeqing ZHU
Non-ExecutiveNaxin YAO, Nisa Bernice Wing-Yu LEUNG, Quan ZHOU, Siu Wai NG
Independent Non-ExecutiveDanke YU, Hong WU, Kwok Tung LI Donald,
Director Yiyou CHEN12.33%
Director Naxin YAO9.71%
Director Nisa Bernice Wing-Yu LEUNG8.59%
Director Yeqing ZHU6.73%
Legend Capital9.90%
SBCVC Fund5.40%
VMS Holdings8.68%
(Year ended Dec 31)
2020 *20192018
Gross Profit16,53534,3183,840
Pre-Taxed Profit(533,485)(106,235)(224,869)
Attributable Profit for the period(533,761)(106,465)(224,869)
* For the nine months ended September 30, 2020.
Offer Price$22.70 - $26.66
Capitalization$9,487m - $11,143m
Unaudited pro forma adj NAV / share$3.04 - $4.49
Assuming the offer price being at the mid-point of $24.68, the net proceeds raised would be HK$1,754.1m, of which:
* $701.6m (40.0%) to fund the commercialization and further development of ColoClear;
* $87.7m (5.0%) to fund ongoing sales and marketing of Pupu Tube;
* $526.2m (30.0%) to fund ongoing and planned research and development;
* $263.1m (15.0%) to be used for continued expansion and diversification of our product portfolio through potential acquisition or in-licensing of product candidates in the cancer screening field; and
* the balance of $175.4m (10.0%) as additional working capital.
Code Name Nominal Change %Change
06606NH HEALTH-Bup62.8000.5500.884%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 14/05/2021 12:44
IPO Calculator
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.